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Ubiquitinationa b s t r a c t
Among the different classes of enzymes involved in the ubiquitin pathway, E2 ubiquitin-conjugating
enzymes occupy a central role in the ubiquitination cascade. Cdc34-like E2 enzymes are character-
ized by a 12–14 residue insertion in the proximity of the catalytic site, known as the acidic loop.
Cdc34 ubiquitin-charging activity is regulated by CK2-dependent phosphorylation and the regula-
tory mechanism involves the acidic loop. Indeed, the phosphorylation stabilizes the loop in an open
conformation that is competent for ubiquitin charging.
Cdc34 is associated with a variety of diseases, such as hepatocellular carcinomas and prostatic
adenocarcinomas. In light of its role, the discovery of potential inhibitory compounds would provide
the mean to effectively modulate its activity.
Here, we carried out a computational study based on molecular dynamics, virtual screening and
docking to identify potential inhibitory compounds of Cdc34, modulating the acidic loop conforma-
tion. The molecules identiﬁed in this study have been designed to act as molecular hinges that can
bind the acidic loop in its closed conformation, thus inhibiting the Cdc34-mediated ubiquitination
cascade at the ubiquitin-charging step. In particular, we proposed a pharmacophore model featur-
ing two amino groups in the central part of the model and two lateral aromatic chains, which
respectively establish electrostatic interactions with the acidic loop (Asp 108 and Glu 109) and a
hydrogen bond with Ser 139, which is one of the key residues for Cdc34 activity.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Ubiquitination is a post-translational modiﬁcation that was
originally known as a signal for protein degradation by the 26S
proteasome [1]. It is also involved in many other different signaling
pathways, including cell cycle, endocytosis, transcription, DNA
repair, signal transduction, apoptosis and the immune response
[1–4].
In the ubiquitination pathway, E2 enzymes charged with ubiq-
uitin (Ub) can be recruited by an E3 ligase, along with the target
substrates. The C-terminal glycine of Ub can then be attached toa lysine residue on the target substrate. This can result in the trans-
fer of only a single Ub molecule (mono-ubiquitination) or the addi-
tion of further Ub molecules to form a poly-Ub chain. Depending
on the target lysine used to cross-link the Ub molecules in the
chain, different poly-Ub chains can be formed, which adopt diverse
three-dimensional (3D) structures and exert different biological
effects [5–8].
Ubiquitination can thus be described as a molecular zip code,
which is used to sort different ubiquitination products to different
destinations. Errors in delivery of ubiquitinated proteins to the
proteasome or other destinations are highly detrimental for the
cell [3].
E2 enzymes (E2s) have a primary role in catalyzing, alone or
with the cognate E3, the covalent attachment of Ub to the target
proteins and they have a major role in deﬁning the topology of
the polyUb chain and thus the fate of the substrate [9]. E2s are
often multi-domain proteins that all share a conserved Ub-binding
domain (UBC characterized by a a/b fold) [9–11]. The highly
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domain formed by a short loop connecting a-helix 2 and a-helix 3
and a long loop (b4-a2 loop) proximal to the active site [9–11].
E2 UBC domains have been recently classiﬁed by Michelle et al.
[12] into 17 families of homologs by performing phylogenetic anal-
yses on 207 E2 genes belonging to seven different species. Family 3
members, i.e. Cdc34-like enzymes are characterized by a conserved
and disordered insertion in the b4-a2 loop in the proximity of the
catalytic site. The insertion is known as the acidic loop of Cdc34-
like enzymes.
In a previous work, we identiﬁed two co-evolving signature ele-
ments in Cdc34-like E2 enzymes: the acidic insertion in b4-a2 loop
in the proximity of the catalytic cysteine and two conserved CK2
phospho-sites within the UBC domain [13]. We previously demon-
strated by combining Ub-charging assays and MD simulations that
the phosphorylation at one of this sites (S130) can modulate the
opening and closing of the b4-a2 loop with respect to the catalytic
cleft and, in turn, it modulates the accessibility of the catalytic Cys
for Ub-charging [13]. More in details, this regulatory mechanism
relies on electrostatic repulsive effects between the phosphory-
lated serine and the acidic residues in the b4-a2 loop. The loop
can undergo a substantial shift and drift away from the catalytic
cleft upon phosphorylation, promoting the accessibility of the cat-
alytic Cys.
Cdc34 is known to be involved in a variety of diseases, such as
hepatocellular carcinomas and prostatic adenocarcinomas [14–19].
In fact, Cdc34 stimulates cellular proliferation by enhancing the
degradation of p53 and p27, which both act as inhibitors of cell
cycle progression.
In light of the above scenario, recent studies have been focused
in the design and identiﬁcation of inhibitory molecules of E2
enzymes and of Cdc34 in particular. A small inhibitor (CC0651)
was identiﬁed for Cdc34 [20,21]. CC0651 was able to inhibit prolif-
eration of human cancer lines and caused accumulation of the p27
substrate. Another small inhibitor was identiﬁed for Rad6 E2s [22]
with the capability to inhibit the thioester formation between the
E2 catalytic cysteine and the C-terminal of Ub. These studies have
opened the venue to study E2 enzymes as a suitable class of drug
targets in the ubiquitination pathway.
We contribute to this scenario, proposing a group of molecules
with the potential to directly counteract the Ub-charging activity
of Cdc34 by acting on the acidic loop (b4-a2 loop) and keeping it
in a closed conformation, shielding the catalytic cysteine needed
for the attachment of the Ub molecule. The task was carried out
by the integration of different computational approaches, as
described by Sanders et al. [22]. In particular, we used a structural
ensemble that was already available thank to our previous MD
studies [13,23] to isolate the most representative conformations
suitable for docking simulations. Subsequently, virtual screening
and docking were performed to select putative compounds from
735,758 entries of the ZINC database [24]. We selected 20 mole-
cules by both energy-based and structural-based screening of
docking simulations of 500 compounds. We then provide a phar-
macophore model with the aim of inhibiting Cdc34 Ub-charging
activity acting as molecular zipper to stabilize the closed and inac-
tive conformation of the acidic loop. The results here described can
provide a valuable dataset for future experimental studies in the
ﬁeld.
2. Materials and methods
2.1. Rmsd-matrices and clustering
The Cdc34 MD ensemble previously published [13] along with
an increased sampling achieved by performing new simulations[23] was used as a reference conformational ensemble for the pres-
ent investigation. In particular, we post-processed the ensemble by
rmsd-based structural clustering as described in the following.
C-alpha (Ca) root mean square deviation (rmsd) were calcu-
lated pairwise for each pair of frames of the available MD ensem-
ble, collecting values ranging from 0.2 to 0.65 nm, indicating
respectively nearly identical or highly diverging structures in the
ensemble. The highest rmsd values are associated to a displace-
ment of the acidic loop conformations, whereas secondary struc-
tures were conserved in all the MD structures and characterized
by rmsd values lower than 0.25 nm [13]. The Ca rmsd matrix
(Fig. 1S) was then processed to obtain structural clusters of similar
conformations using the Gromos algorithm implemented in Gro-
macs (www.gromacs.org) with a clustering cutoff of 0.35 nm.
2.2. Virtual screening and docking simulations
The virtual screening and the docking calculations were per-
formed with DOCK Blaster [25] and Autodock version 4.2 [26],
respectively. DOCK Blaster is an online server that selects and
scores thousands of compounds deposited in the ZINC database
[24] for a target structure uploaded by the user. The center of mass
of three residues (P110, I137 and N138) was used to set the grid for
the calculation. In particular, we selected the ZINC subset 11 [24],
containing 735,758 entries. Indeed, compounds belonging to this
subset are described as lead-like and were selected to obey to
the Lipinski rule [27], according to which an orally active drug
has no more than one violation of the following criteria: not more
than ﬁve hydrogen-bond (H-bonds) donors (nitrogen or oxygen
atoms with one or more hydrogen atoms), no more than ten H-
bond acceptors (nitrogen or oxygen atoms), a molecular weight
under 500 Da and an octanol–water partition coefﬁcient log P less
than 5.
Once the virtual screening procedure was completed, we
employed Autodock version 4.2 [26] for docking calculations of
the ﬁrst 500 compounds selected by DOCK Blaster energy-rank.
For each molecule, DOCK Blaster provided one binding pose char-
acterized by the lowest energy according to the DOCK Blaster
energy function. The DOCK Blaster binding pose was used as a
starting structure for docking simulations with Autodock for each
molecule (500 Autodock simulations overall). The parameters used
for Autodock simulations are reported in the Supplementary
Table 1S.
Autodock provided different binding poses for each of the 500
molecules simulated. For each molecule, the binding poses gener-
ated by Autodock are at ﬁrst clusterized by the Autodock internal
routines. For each cluster referred to a speciﬁc molecule, the soft-
ware generally returns the binding pose with the lowest energy
(cluster binding pose). We then applied a further selection proce-
dure by the Pymol Python APIs (application programming inter-
faces) on all the cluster binding poses provided by Autodock for
each molecule. In particular, we used both energetic and struc-
tural criteria in this ﬁnal selection step. The ﬁnal goal is to obtain,
for each of the 500 screened molecules, a unique binding pose
that is not only characterized by the lowest energy but also that
can structurally act as a molecular zipper contacting both the
acidic loop and the surrounding region in the catalytic cleft, as
also discussed in the Results. With this aim in mind, we ranked
by the Python routine with the Pymol APIs the cluster binding
poses referred to the same molecule according to their energy.
Among the two cluster binding poses of a molecule that are char-
acterized by the lowest energy, the API routine selects the one
that has a center of mass at the minimal distance from the bind-
ing site (deﬁned using as reference residues P110, I137 and
N138).
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3.1. Selection of the starting structure for virtual screening
To select a suitable Cdc34 structure for docking simulations, we
post-processed the previously published MD ensemble of Cdc34
[13,23].
A Ca rmsd matrix (Fig. 1S) was built from the MD ensemble to
evaluate the conformational variability among the collected struc-
tures. A clustering algorithm was then used to extract from the
rmsd matrix different clusters of similar conformations (Fig. 1S,
see Section 2 for details). In particular, we identiﬁed a highly pop-
ulated cluster that also includes the conformations from the most
populated basin of the previously published free energy landscape
[13]. The Cdc34 structure selected for virtual screening and dock-
ing simulations is the average conformation associated with this
cluster. Indeed, it can be considered representative of the closed
and inactive conformation of Cdc34, i.e. with the acidic loop in a
closed conformation and the catalytic cysteine in a buried position
(Fig. 1).
3.2. Selection of a binding site for the inhibitors
The binding site was selected according to the position and ori-
entation of the acidic loop. We aimed at identifying molecules that
can act as molecular zippers, i.e. able to stabilize the loop in the
closed and inactive conformation so that the Ub-charging activity
can be impaired. Thus, a potential inhibitor should establish strong
intermolecular interactions with the acidic residues in the b4-a2
loop and, at the same time, it should be able to bind the surround-
ing regions of the catalytic cleft to maintain the loop in the closed
conformation. In particular, we selected three residues of Cdc34
(P110, I137 and N138) whose center of mass corresponds to a cav-Fig. 1. Cdc34 three-dimensional structure. The acidic loop is represented in yellow,
while the catalytic cysteine in red. The three residues (P110, I137 and N138)
selected to deﬁne the binding site for virtual screening are depicted in cyan (right
panel). (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)ity located in the close proximity of the catalytic cysteine and the
acidic loop (Fig. 1). The selection of this binding site was essential
to establish a spatial grid as an input for the docking algorithm that
we employed in the ﬁrst screening step (DOCK Blaster). Among the
735,758 molecules in the ZINC database (ZINC subset 11), the soft-
ware returned 500 compounds ranked according to their binding
free energies.
DOCK Blaster parameters are optimized for virtual screening
calculations and thus they only permit a fast but coarse selection
among the large number of molecules deposited in the ZINC subset
11. Thus to reﬁne our data, we performed docking simulations with
Autodock for each of the 500 molecules returned by DOCK Blaster
(see Section 2). In particular, these 500 compounds were docked
against Cdc34 structure, and the Autodock grid was built around
the selected binding site in Fig. 2S, which also corresponds to the
same search space used for the DOCK Blaster calculations.
From a ﬁrst visual inspection of the binding poses selected by
Autodock internal routines (cluster poses, see Section 2 for details),
it was not possible to detect any common feature that could be
used to build a pharmacophore model (Fig. 2 and Table 1). There-
fore a subsequent selection step was applied to ﬁlter out the mol-
ecules that did not properly interact with Cdc34, In particular, we
analyzed the clusters calculated by Autodock for each different
compound to select molecules that may either bind Cdc34 with
high afﬁnity (poses that have the lower energies in the ranking)
and act as molecular hinges/zippers by both interacting with the
acidic loop and the surrounding structural components (poses at
the lower distances from the binding site) (see Section 2). The
poses of each of the 500 molecules were classiﬁed into three bins
according to their distance from the binding site (Fig. 3) so that
molecules belonging to the ﬁrst bin had a center of mass at a dis-
tance shorter than 0.8 nm from the center of mass of the previously
deﬁned binding site. This step is of crucial importance, since the
inhibitors are expected to act as molecular hinges and therefore
need to establish interactions with residues at the opposite sides
of the acidic loop. According to these criteria, we selected a binding
pose for each of the 500 molecules (see Section 2 for further
details). After this post-clustering ranking procedure, the ﬁrst 20
lower energy molecules (Fig. 4, left panel) are all located in the
same area of the binding site and share recurring structural
features that are discussed in details below.Fig. 2. Autodock results upon clustering with Autodock internal routines. The ﬁrst
20 molecules from the Autodock energy-ranking list are depicted with different
colors. The residues of the acidic loop are shown as yellow sticks. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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clustering and the post-clustering selection procedure that we
applied. Indeed, the ﬁrst nine molecules belonging to the ﬁrst bin
of the post-clustering procedure were also found in the Autodock
ranking, as shown in Table 1. Nevertheless, the ranking order after
post-clustering selection with API tools is signiﬁcantly modiﬁed. In
particular, the molecules belonging from 9th to 20th position in
the post-clustering ranking do not appear in the ﬁrst 20 positions
of the classical Autodock energy-based ranking (Table 1).
We emphasize the need for a spatial clustering procedure by
showing in Fig. 5 the different positions for two molecules used
as examples of the two possible scenarios, i.e. a case that is selected
by the post-clustering ranking (left panel) and a case that is dis-
carded upon this procedure (right panel). The left panel illustrates
the orientation of the molecule C08743791 (4,6-dimethyl-N-[3-(5-
phenyl-1H-pyrazol-3-yl)-1H-1,2,4-triazol-5-yl]pyrimidin-2-amine),Table 1
Docking results with Autodock before and after the clustering procedure.
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2-amine) establish two H-bonds with the acidic residues in the
loop.
Another recurrent feature of the selected molecules is the pres-
ence of an aromatic ring that is shown to interact with S139 (Fig. 7).
Indeed, Cdc34 S139 was identiﬁed as a critical determinant for sub-
strate mono-ubiquitination and polyubiquitination via K48-linked
ubiquitination by experimental mutagenesis [28]. Moreover, it is
the homologous residue of Ubc7 D127 that is known to play a cru-
cial role in positioning the acceptor lysine of the substrate for the
nucleophilic attack of the thioester bond during catalysis [29].
The aromatic ring of the scaffold (compound C08743791 [4,6-
dimethyl-N-[3-(5-phenyl-1H-pyrazol-3-yl)-1H-1,2,4-triazol-5-
yl]pyrimidin-2-amine] is reported as proof of concept in Fig. 8) is
shown to interact with two hydrophobic residues in helix a3 of
Cdc34: V143 and V147. This interaction might account for the
speciﬁcity of the compounds. The valine steric hindrance can also
limit the size of the inhibitor into the binding site.
In summary, on the basis of these common chemical features,
we propose a pharmacophore model (Fig. 9) which features three
main regions: a central region constituted by two amino groups
which interact with the acidic residues of the loop, and two lateral
regions that are characterized by the recurring presence of aro-
matic groups.
4. Discussion
The ubiquitin pathway is responsible for protein regulation by
promoting target substrates degradation via the 26S proteasome
system, and its deregulation has been implicated in a variety of dis-
eases, including the onset of cancer and neurodegenerative disor-
ders. In light of this crucial role, ubiquitination mechanisms have
been thoroughly investigated to discover new leads to modulate
cell cycle progression, as well as to ﬁnd suitable molecular targets
for cancer treatment.In particular, E2 enzymes have been shown to play a central role
in ubiquitination, since they act as mediators in determining the
ultimate fate of the substrates. In this context, they have been
recently proposed as suitable targets for inhibitory compounds
[20–22].
In this context, we here focused on the human E2 enzyme
Cdc34, which has been directly linked to tumorigenesis [14–19].
In particular, we used here as a model system, the homolog of
Cdc34 in yeast, Saccharomyces cerevisiae Cdc34 (ScCdc34 or
Ubc3). Indeed, this enzyme has been extensively characterized by
our and other works [13,23,30–33] and an MD ensemble of confor-
mations for ScCdc34 was already available [13,23]. ScCdc34 repre-
sents a valuable model since it shares a high sequence similarity
with its human homolog (Fig. 3S). It has also been used as a model
for studying the relationship occurring between phosphorylation
and regulation of the E2 enzymatic activity [13]. We here focused
on the Cdc34 acidic loop as a possible target of action for inhibitory
molecules, which can constrain its position in the proximity of the
catalytic cysteine, impairing Cdc34 activity. Indeed, the current
data available on Cdc34 [13,23,30–33] support that Cdc34 can pop-
ulate both states in which the loop is in a ’closed’ conformation and
the catalytic cysteine not accessible for Ub-transfer by the E1
enzyme, and active ‘open’ state in which the loop is open or par-
tially open and the catalytic cysteine in a solvent-exposed position
that can thus be compatible with Ub-charging. Those active open
states, which are likely to be present even in absence of phosphor-
ylation, are suggested to be further promoted by phosphorylation
of Cdc34 catalytic domain by a population-shift mechanism
[13,23]. The aim of our work is to identify molecules with the
potential of entrapping the inactive states of Cdc34, i.e. a confor-
mation of the protein in which the loop is stabilized in a closed
state and the catalytic cysteine is thus buried and not accessible
for Ub-transfer.
In this work, MD simulations of ScCdc34 were thus analyzed to
select a conformation suitable for docking simulations. A large
Fig. 3. Histogram distribution of the distances calculated between the docked molecules and the residues selected for the Autodock grid construction (P110, I137 and N138).
Fig. 4. Molecules identiﬁed by the post-clustering ranking according to both structural and energetic criteria. In the left panel, the ﬁrst 20 high-ranking molecules after
clustering and a portion of Cdc34 are depicted with surface representation of molecule C08743791. In the right panel, the high-ranking clustered molecules are shown
superimposed to underline the presence of two recurrent amino groups. The selection step has been carried out post-processing Autodock output with Phyton Pymol API
tools.
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screening against ScCdc34 structure, followed by docking simula-
tions with Autodock to reﬁne the results. More in details, the pipe-
line that we have followed is constituted by a ﬁrst step of coarse
molecular selection based on shape complementarity performed
by DOCK Blaster, screening the ZINC database. In a second step
500 compounds selected at the ﬁrst step were re-docked in the
Cdc34 binding site by Autodock and a ﬁltering procedure was
applied based on both spatial criteria and binding free energy to
identify 20 molecules. It has to be noted that all the molecules
selected from our in silico screening come from the ZINC database
and comply with the Lipinski rule of ﬁve [27], so that for each
compound the octanol–water partition coefﬁcient is not greater
than 5 and the molecular mass is less than 500 Da. These two fea-
tures, along with a number of hydrogen-bond donor/acceptor
groups lower than ﬁve make the selected molecules likely to dif-
fuse inside cell membranes, so that they can exert their biological
activity.
In the ﬁrst part of the work, we performed a preliminary screen-
ing on thousands of compounds from a subset of the ZINC database
using DOCK Blaster. One could argue that 500 molecules are not a
sufﬁcient dataset to further investigate. In this context, it has to be
noted despite being less accurate than Autodock in its predictions,
DOCK Blaster recapitulates the crystal ligand pose within 2 Å rmsd
50–60% of the time in common benchmarks [25]. We hereanalyzed in details the structural features which the majority of
the 500 hundred molecules returned by DOCK Blaster have in com-
mon. These features are more clearly distinguishable after the fol-
lowing screening performed with Autodock and the spatial
ﬁltering (Fig. 9). Hence, the presence of distinct common chemical
and structural determinants in the subset of molecules selected by
DOCK Blaster supports reliability of its results, so that it is unlikely
that from a random selection of ZINC molecules we could have
obtained similar results.
In the 20 molecules identiﬁed in our screening, a set of common
structural features can indeed be identiﬁed used to design a phar-
macophore model. From an energetic point of view, the most rele-
vant intermolecular interactions are established by two amino
groups, which form two H-bonds with carboxylic groups from
the acidic loop (D108 and E109). These interactions account for
much of the calculated binding free energy, and therefore have
been used by the energy-based ranking as the main discriminating
feature for molecular selection. To quantitatively assess the impor-
tance of these hydrogen bonds on the binding free energy for each
molecule, we also separately evaluated each energy component. As
shown in Fig. 10, for the ﬁrst four high-ranking molecules, the
energy contribution of the hydrogen bonds accounts for more than
80% of the free energy of binding, as expected. In addition to the
interactions established with the acidic loop, the selected com-
pounds share a recurrent hydrogen bond with the Ser 139, that
Fig. 5. Examples of binding poses for the molecules. The left panel and right panels show the orientation of molecule C08743791 (4,6-dimethyl-N-[3-(5-phenyl-1H-pyrazol-
3-yl)-1H-1,2,4-triazol-5-yl]pyrimidin-2-amine), and molecule C20209924 (5-methyl-N-{2-[3-(3-pyridinyl)-1H-1,2,4-triazol-5-yl]ethyl}-2-indolinecarboxamide), respec-
tively. The ﬁrst molecule is an example of molecule with an orientation suited for the interaction with both the acidic loop and the surrounding structural components (V143
and V147), while the latter is only interacting with the acidic loop and belongs to the subset of compounds that has been discarded upon the ﬁnal selection step with API
tools.
Fig. 6. Interactions between the selected molecules and D108 and E109 residues of
the acidic loop. Molecule C08743791 (4,6-dimethyl-N-[3-(5-phenyl-1H-pyrazol-3-
yl)-1H-1,2,4-triazol-5-yl]pyrimidin-2-amine) is reported as an example and the
hydrogen bonds with D108 and E109 of the acidic loop are highlighted.
Fig. 7. Interactions between the selected molecules and S139. (Left panel) Aromatic rings are highlighted as a recurrent feature of the high-ranking molecules. (Right panel)
The aromatic ring of compound C29375629 (2-(2-bromo-4,6-diﬂuoro-anilino)-2-oxo-ethyl]) is shown to interact with S139.
Fig. 8. Interactions between the selected molecules and valine residues in Cdc34
catalytic cleft. The aromatic ring of molecule C08743791 (4,6-dimethyl-N-[3-(5-
phenyl-1H-pyrazol-3-yl)-1H-1,2,4-triazol-5-yl]pyrimidin-2-amine) is reported as
an example of interaction with V143 and V147 located on helix a3 of Cdc34.
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Fig. 9. Pharmacophore model for Cdc34 inhibitors. The three main areas required for the inhibition of the acidic loop of Cdc34 are highlighted.
Fig. 10. Binding free energy of the top four compounds of the post-clustering ranking. The ﬁrst bar (light blue) refers to the total binding free energy (full list reported in
Table 1), the second bar (light yellow) is the internal energy obtained as the sum of the H-bonds (and VdW contributions) (olive green) and the electrostatic component
(gray). The last column (red) refers to the torsional energy. Binding free energy = internal energy + torsional energy. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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484 A. Arrigoni et al. / FEBS Open Bio 4 (2014) 473–484has been reported to be a crucial residue for Cdc34-mediated ubiq-
uitination [28]. An aromatic ring able to interact with a valine clus-
ter of Cdc34 also contributes to the molecular scaffold.
5. Conclusion
E2 enzymes act as mediators in determining the ultimate fate of
the substrates selected for ubiquitination and for this reason they
are considered privileged sites of action for inhibitory compounds.
In the present work, we performed a virtual screening proce-
dure to select compounds, which may act as inhibitor for the cat-
alytic activity of Cdc34, an E2 enzyme who has been directly
linked to tumorigenesis [14–19]. In particular, the molecules were
selected to target Cdc34 acidic loop, a structural component that
has been shown to modulate Cdc34 enzymatic activity [13].
One of the problems that typically affect virtual screening pro-
cedures performed on thousands of compounds is the high number
of false positives which lowers conﬁdence of calculations results.
To overcome this bias, we used at ﬁrst DOCK Blaster, whose pur-
pose is to provide a fast but coarse analysis of the entire Zinc sub-
set, followed by Autodock calculations performed on the 500 high-
ranking compounds selected by DOCK Blaster. After further reﬁne-
ment of the docking results, we have built a pharmacophore model
from the ranked list of selected molecules, which can be a useful
scaffold to develop and test inhibitory molecules for Cdc34in
future experimental studies.
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